Is Roprostim/Romigrastim a domestic drug?

Romiplostim is a drug used to treat chronic idiopathic thrombocytopenia (ITP). ITP is an immune disease in which a patient's immune system mistakenly attacks and destroys platelets, causing platelet counts to be too low and increasing the risk of bleeding. Romigrastim/romigrastim promotes platelet production by activating the thrombopoietin receptor, helping a patient's megakaryocytes to produce platelets at a faster than normal rate, thus counteracting the immune system's ability to destroy platelets.

Roprestim was originally developed by a foreign pharmaceutical company (Amgen) and has been approved for marketing overseas by U.S. Food and Drug Administration (FDA) and other authoritative agencies. However, domestic pharmaceutical companies have also made progress in recent years. For example, Qilu Pharmaceutical’s Ropremilast for injection (Ruilisheng) has been approved for marketing by the State Food and Drug Administration, becoming the first biosimilar Ropremilast approved for marketing in China. This shows that in the field of romiplostim/romigrastim, domestic pharmaceutical companies already have R&D and production capabilities that are in line with international standards.

As an innovative drug, Roprostim has corresponding clinical advantages. Its long-acting and sustained-release feature allows patients to use it only once a week, greatly improving the convenience of treatment and patient compliance. At the same time, the drug also has good safety and tolerability. Multiple clinical studies have shown that it does not increase the incidence of thrombotic events and has no significant impact on liver function.

However, despite the introduction of domestic versions, patients still need to be cautious when choosing to use them. Patients should consult their doctors regarding the efficacy, safety, and side effects of drugs to determine the most suitable treatment plan for their condition.